GGHC
VKTX icon

Gilder Gagnon Howe & Co’s Viking Therapeutics VKTX Stock Holding History

Gilder Gagnon Howe & Co’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-16,678
Closed -$671K – 266
2024
Q4 		$671K Buy
+16,678
New +$951K 0.01% 227

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Gilder Gagnon Howe & Co's VKTX Position: Q1 2025 in Review

Gilder Gagnon Howe & Co sold out of Viking Therapeutics (VKTX) in Q1 2025, closing a stake of 16,678 shares — an estimated $671K sold.

Gilder Gagnon Howe & Co first reported a position in VKTX in Q4 2024 and held it in 1 quarter. The position peaked at $671K in Q4 2024. 372 funds tracked by Wall St. Rank hold VKTX as of Q1 2025.

  • Gilder Gagnon Howe & Co reported no remaining Viking Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Gilder Gagnon Howe & Co sold 16,678 Viking Therapeutics shares in Q1 2025, an estimated $671K.
  • Gilder Gagnon Howe & Co first reported a position in Viking Therapeutics in Q4 2024 and held it in 1 quarter.
  • Gilder Gagnon Howe & Co's Viking Therapeutics position peaked at $671K in Q4 2024.
  • 372 funds tracked by Wall St. Rank held Viking Therapeutics as of Q1 2025.

Based on Gilder Gagnon Howe & Co's 13F filing for Q1 2025, filed 15 May 2025.